Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Antivir Ther. 2015 Nov 10;21(4):297–306. doi: 10.3851/IMP3006

Table 3.

Average final effectiveness for danoprevir monotherapy, mericitabine monotherapy and the combination of danoprevir and mericitabine

Cohort Danoprevir
dose
(regimen)		 Mericitabine
dose (regimen)		 Danoprevir final
effectiveness
(time to 90%, 99%
final effectiveness)		 Mericitabine final
effectiveness
(time to 90%, 99%
final effectiveness)		 Combination
final
effectiveness
A1 100 mg (tid)
D4-7		 500 mg (bid)
D1-7		 0.993
(1.9 hrs, 17.0 hrs)		 0.652
(3.4 days, 8.4 days)		 0.998
A2 100 mg (tid)
D1-7		 500 mg (bid)
D4-7		 0.993
(1.9 hrs, 17.0 hrs)		 0.652
(3.4 days, 8.4 days)		 0.998
B 100 mg (tid)
D1-14		 500 mg (bid)
D1-14		 0.993
(1.9 hrs, 17.0 hrs)		 0.652
(3.4 days, 8.4 days)		 0.998
C1 200 mg (tid)
D1-14		 500 mg (bid)
D1-14		 0.997
(1.0 hrs, 9.6 hrs)		 0.652
(3.4 days, 8.4 days)		 0.999
C2 100 mg (tid)
D1-14		 1000 mg (bid)
D1-14		 0.993
(1.9 hrs, 17.0 hrs)		 0.789
(2.5 days, 7.2 days)		 0.999
D 200 mg (tid)
D1-14		 1000 mg (bid)
D1-14		 0.997
(1.0 hrs, 9.6 hrs)		 0.789
(2.5 days, 7.2 days)		 0.999
E 600 mg (bid)
D1-14		 1000 mg (bid)
D1-14		 0.998
(0.48 hrs, 5.0 hrs)		 0.789
(2.5 days, 7.2 days)		 0.9996
F 900 mg (bid)
D1-14		 1000 mg (bid)
D1-14		 0.999
(0.24 hrs, 3.4 hrs)		 0.789
(2.5 days, 7.2 days)		 0.9998
G 900 mg (bid)
D1-14		 1000 mg (bid)
D1-14		 0.999
(0. 24 hrs, 3.4hrs)		 0.789
(2.5 days, 7.2 days)		 0.9998